Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Gavin Clark-Gartner maintains an Outperform rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $62 to $66.
August 08, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group analyst Gavin Clark-Gartner maintains an Outperform rating on Mirum Pharmaceuticals and raises the price target from $62 to $66.
The raised price target and maintained Outperform rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100